Restrictions Imposed On Open And Uncontrolled Sale Of Drugs Used For Drug Addiction

Hanumangarh:  Open and uncontrolled sale of drugs used for intoxication has been banned in Hanumangarh. District Collector and District Magistrate Kanaram issued an order on Thursday to prevent drug abuse. This important decision has been taken for the bright future of the youth under the powers conferred under Section 163 of the Bharatiya Nagarik Suraksha Sanhita, 2023.

According to the order, some medicines in the district, which are not defined as intoxicants under the NDPS Act, are being used for intoxication in the form of tablets or injections. These include medicines such as Pregabalin, Tapentadol, Zopiclone salt based. These are also called Signature, Jodier, Green Parrot, Orange, Green Capsule and Blue Ford in the local language.

Now wholesale and retail drug sellers or other unauthorized persons or firms will not buy and sell medicines of more than 75 mg of Pregabalin. These medicines cannot be sold without a purchase-sale bill. Wholesale drug sellers will maintain a daily stock register of all purchases and sales of these medicines along with the batch number. Its date-wise information will have to be sent every week to the e-mail ID of the Superintendent of Police office. Retail drug sellers will sell them only by marking their seal and date on the original prescription/slip of the doctor.

Instructions for surprise inspection

As per the orders of the District Collector and District Magistrate, the Assistant Drug Controller will check the monthly report of purchase and sale of salt based medicines of wholesale and retail drug sellers. The Assistant Drug Controller will conduct surprise inspections of medical stores by forming teams in mutual coordination with the concerned Sub-Divisional Officer and Police Department. The District Collector and District Magistrate will be informed about the actual situation.

Violation of the order and irregularities can prove costly for medical stores. The police administration or the subdivision officer will take action to punish under Section 223 of the Indian Code of Justice. This order will be effective from 18 September 2024 for the next 2 months.

Related Posts

Centre bans fixed-dose combination for Common Cold in children below four

The ministry said the use of “Chlorpheniramine Maleate and Phenylephrine Hydrochloride” drug combination in children below four years could pose health risks, while their safer alternatives are available in the…

New research study proposes a unifying theory for Alzheimer’s disease and other neurodegenerative diseases

A new peer-reviewed paper by neuroscientist Dale E. Bredesen proposes a unifying framework that could fundamentally change how researchers understand Alzheimer’s disease and other neurodegenerative disorders. Published on August 11…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Centre bans fixed-dose combination for Common Cold in children below four

Centre bans fixed-dose combination for Common Cold in children below four

New research study proposes a unifying theory for Alzheimer’s disease and other neurodegenerative diseases

New research study proposes a unifying theory for Alzheimer’s disease and other neurodegenerative diseases

Brain organoid maturation is driven by a lifelike developmental clock: Study

Brain organoid maturation is driven by a lifelike developmental clock: Study

Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses